RBM3 has been shown to be a prognostic biomarker in several cancers, e.g. urothelial cancer[12], breast cancer[7], colorectal cancer[10], prostate cancer[9], esophageal and gastric adenocarcinoma[18] and ovarian cancer[8]. Here, RBM3 is linked to breast carcinoma.